Jacobio Pharmaceuticals Group Co., Ltd.
HKEX:1167.HK
8.11 (HKD) • At close August 29, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2024 Q4 | 2024 Q2 | 2023 Q4 | 2023 Q2 | 2022 Q4 | 2022 Q2 | 2021 Q4 | 2021 Q2 | 2020 Q4 | 2020 Q2 | 2019 Q4 | 2019 Q2 | 2018 Q4 | 2018 Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 155.708 | 0 | 23.185 | 40.335 | 41.059 | 54.687 | 95.12 | 57.689 | 486.286 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 22.384 | 37.933 | 37.258 | 45.854 | 86.846 | 53.133 | 44.115 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 155.708 | 0 | 0.801 | 2.402 | 3.801 | 8.833 | 8.274 | 4.556 | 442.171 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 1 | 0 | 0.035 | 0.06 | 0.093 | 0.162 | 0.087 | 0.079 | 0.909 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 153.35 | 176.827 | 173.568 | 198.752 | 269.058 | 176.589 | 159.178 | 121.66 | 114.94 | 71.012 | 84.847 | 54.129 | 42.444 | 42.444 |
| General & Administrative Expenses
| 21.861 | 21.19 | 22.9 | 23.715 | 19.772 | 22.779 | 26.05 | 18.528 | 41.464 | 12.374 | 64.231 | 6.85 | 2.956 | 2.956 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 21.861 | 21.19 | 22.9 | 23.715 | 19.772 | 22.779 | 26.05 | 18.528 | 41.464 | 12.374 | 64.231 | 6.85 | 2.956 | 2.956 |
| Other Expenses
| -17.22 | -12.127 | 17.648 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -26.453 | -26.453 |
| Operating Expenses
| 157.991 | 185.89 | 214.116 | 186.965 | 262.588 | 144.247 | 183.72 | 148.494 | 1,146.582 | 812.116 | 272.505 | 157.695 | 52.648 | 52.648 |
| Operating Income
| -2.283 | -185.89 | -213.315 | -222.107 | -292.734 | -188.191 | -163.007 | -129.307 | 290.28 | -80.106 | -142.318 | -58.118 | -50.717 | -50.717 |
| Operating Income Ratio
| -0.015 | 0 | -9.201 | -5.507 | -7.13 | -3.441 | -1.714 | -2.241 | 0.597 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 15.627 | 16.837 | 20.477 | 55.826 | 48.698 | 60.366 | 10.856 | 7.341 | -993.053 | -730.798 | -134.061 | -96.937 | -27.251 | -27.251 |
| Income Before Tax
| 13.344 | -169.053 | -192.838 | -166.281 | -244.036 | -127.825 | -164.59 | -136.597 | -702.773 | -810.904 | -270.762 | -155.055 | -77.968 | -77.968 |
| Income Before Tax Ratio
| 0.086 | 0 | -8.317 | -4.122 | -5.944 | -2.337 | -1.73 | -2.368 | -1.445 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 0 | -0 | -0 | 0 | 0 | 0 | -0.014 | -0.008 | -0.068 | -0.938 | 0 | 0 |
| Net Income
| 13.344 | -169.053 | -192.838 | -166.281 | -244.036 | -127.825 | -164.59 | -136.597 | -702.759 | -810.896 | -270.694 | -154.117 | -74.606 | -74.606 |
| Net Income Ratio
| 0.086 | 0 | -8.317 | -4.122 | -5.944 | -2.337 | -1.73 | -2.368 | -1.445 | 0 | 0 | 0 | 0 | 0 |
| EPS
| 0.017 | -0.22 | -0.24 | -0.22 | -0.32 | -0.17 | -0.22 | -0.183 | -0.93 | -1.08 | -0.36 | -0.2 | -0.1 | -0.1 |
| EPS Diluted
| 0.017 | -0.22 | -0.24 | -0.22 | -0.32 | -0.17 | -0.22 | -0.183 | -0.93 | -1.08 | -0.36 | -0.2 | -0.1 | -0.1 |
| EBITDA
| -15.554 | -176.802 | -188.973 | -212.151 | -291.929 | -181.783 | -161.152 | -124.422 | 291.142 | -75.233 | -139.39 | -51.781 | -46.188 | -46.188 |
| EBITDA Ratio
| -0.1 | 0 | -8.151 | -5.26 | -7.11 | -3.324 | -1.694 | -2.157 | 0.599 | 0 | 0 | 0 | 0 | 0 |